ClinicalTrials.gov
public full text
Public Domain
COVID-19 Methylene Blue Antiviral Treatment
This is a pilot study of a single-center, blind, randomized, placebo-controlled, parallel-group study testing for the efficacy and safety of Methylene blue when administered topically as a 0.02% solution for nasopharyngeal and oropharyngeal irrigation in COVID-19 patients requiring hospitalization.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Exchange Transfusion Versus Plasma From Convalescent Patients With Methylene Blue in Patients With COVID-19#913555
- High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza#883099
- Prevention of Oral Mucositis in Head and Neck Cancer.#992989
- Post Exposure Prophylaxis in Healthcare Workers Exposed to COVID-19 Patients#896640
- Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada)#903374
Record · ID 868554
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive